First-in-human, proof-of-concept phase I trial evaluating the tolerability, pharmacokinetics and efficacy of RG 101 in healthy volunteers and in patients with hepatitis C
Latest Information Update: 30 Mar 2017
At a glance
- Drugs RG 101 (Primary) ; Simeprevir
- Indications Hepatitis C
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Regulus Therapeutics
- 11 Mar 2017 Results assessing immune phenotype and function of NK and T cells (n=32), published in the Hepatology
- 10 Jan 2017 Results assessing safety and tolerability, pharmacokinetics, and antiviral effect of a single dose of RG-101 in patients with chronic HCV infection (n=32) published in the Lancet.
- 17 Apr 2016 Sequence analysis for resistance monitoring of 32 patients were presented at The International Liver Congress™ 2016.